The angiopoietin/Tie2 axis is therefore an attractive target for cancer therapy, since it is involved in inflammation, metastasis and lymphangiogenesis, and drugs such as trebananib have been designed to block Tie2 receptor interaction with angiopoeitin ligands [47]. Here, TEK is linked to cancer.